Literature DB >> 15222980

Anti-inflammatory effects of alpha-melanocyte-stimulating hormone against rat endotoxin-induced uveitis and the time course of inflammatory agents in aqueous humor.

Tomomi Nishida1, Shoji Miyata, Yoshiki Itoh, Nobuhisa Mizuki, Kazuhiro Ohgami, Kenji Shiratori, Iliyana Bozhidarova Ilieva, Shigeaki Ohno, Andrew W Taylor.   

Abstract

PURPOSE: We examined the effects of the immunosuppressive neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) on rat endotoxin-induced uveitis, and to measure the expression of inflammatory cytokines and chemokines with and without the alpha-MSH treatment over the course of the disease.
METHODS: We injected Lewis rats once with Salmonella typhimurium lipopolysaccharide (LPS) to induce uveitis. The rats were given intravenous injections of 250, 500 or 1000 microg of alpha-MSH. The eyes were examined over the next 24 h for inflammation. Aqueous humor was collected 6, 12 and 24 h after endotoxin injections and the number of infiltrating cells were counted in anterior chamber. In addition, we assayed the concentration of protein, nitric oxide, TNF-alpha, IL-6, MCP-1 and MIP-2.
RESULTS: Rats injected with alpha-MSH showed a significant decrease in the number of infiltrating cells in anterior chamber. Moreover, alpha-MSH-treated rats with endotoxin-induced uveitis (EIU) showed significantly lower concentrations of protein, nitric oxide, proinflammatory cytokines and chemokines in their aqueous humor. Even the early stages of EIU were suppressed by the injection of alpha-MSH.
CONCLUSIONS: Our results demonstrate that the immunosuppressive neuropeptide alpha-MSH inhibits the early induction events of endotoxin-induced inflammation in the eye; therefore, suppresses the subsequent infiltration of cells and intraocular production of inflammatory cytokines and chemokines in eyes. alpha-MSH has a possibility of being a therapeutic strategy for anterior uveitis.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15222980     DOI: 10.1016/j.intimp.2004.04.011

Source DB:  PubMed          Journal:  Int Immunopharmacol        ISSN: 1567-5769            Impact factor:   4.932


  17 in total

Review 1.  Negative regulators that mediate ocular immune privilege.

Authors:  Andrew W Taylor; Tat Fong Ng
Journal:  J Leukoc Biol       Date:  2018-02-12       Impact factor: 4.962

2.  The immunomodulating neuropeptide alpha-melanocyte-stimulating hormone (alpha-MSH) suppresses LPS-stimulated TLR4 with IRAK-M in macrophages.

Authors:  A W Taylor
Journal:  J Neuroimmunol       Date:  2005-05       Impact factor: 3.478

Review 3.  Applications of the role of α-MSH in ocular immune privilege.

Authors:  Andrew W Taylor; Darren Lee
Journal:  Adv Exp Med Biol       Date:  2010       Impact factor: 2.622

4.  The neuropeptide alpha-melanocyte-stimulating hormone is critically involved in the development of cytotoxic CD8+ T cells in mice and humans.

Authors:  Karin Loser; Thomas Brzoska; Vinzenz Oji; Matteo Auriemma; Maik Voskort; Verena Kupas; Lars Klenner; Cornelius Mensing; Axel Hauschild; Stefan Beissert; Thomas A Luger
Journal:  PLoS One       Date:  2010-02-01       Impact factor: 3.240

5.  Local treatment with alpha-melanocyte stimulating hormone reduces corneal allorejection.

Authors:  Pedram Hamrah; Zdenka Haskova; Andrew W Taylor; Qiang Zhang; Bruce R Ksander; M Reza Dana
Journal:  Transplantation       Date:  2009-07-27       Impact factor: 4.939

6.  A role for tumor necrosis factor-alpha in experimental Bacillus cereus endophthalmitis pathogenesis.

Authors:  Raniyah T Ramadan; Andrea L Moyer; Michelle C Callegan
Journal:  Invest Ophthalmol Vis Sci       Date:  2008-06-27       Impact factor: 4.799

7.  Injection of an alpha-melanocyte stimulating hormone expression plasmid is effective in suppressing experimental autoimmune uveitis.

Authors:  D J Lee; D J Biros; A W Taylor
Journal:  Int Immunopharmacol       Date:  2009-05-06       Impact factor: 4.932

8.  The diminishment of experimental autoimmune encephalomyelitis (EAE) by neuropeptide alpha-melanocyte stimulating hormone (alpha-MSH) therapy.

Authors:  Andrew W Taylor; Nobuyoshi Kitaichi
Journal:  Brain Behav Immun       Date:  2008-01-02       Impact factor: 7.217

9.  Ocular immune privilege.

Authors:  A W Taylor
Journal:  Eye (Lond)       Date:  2009-01-09       Impact factor: 3.775

10.  alpha-MSH related peptides: a new class of anti-inflammatory and immunomodulating drugs.

Authors:  Thomas A Luger; Thomas Brzoska
Journal:  Ann Rheum Dis       Date:  2007-11       Impact factor: 19.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.